Apellis Pharmaceuticals, Inc.
APLS
$17.49
-$0.05-0.29%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -197.88M | -250.10M | -332.89M | -417.27M | -528.63M |
| Total Depreciation and Amortization | 1.80M | 1.83M | 1.83M | 1.81M | 1.78M |
| Total Amortization of Deferred Charges | 1.56M | 1.05M | 464.00K | 300.00K | 297.00K |
| Total Other Non-Cash Items | 125.01M | 131.39M | 132.09M | 133.00M | 132.06M |
| Change in Net Operating Assets | -18.36M | -89.26M | -209.77M | -267.93M | -200.25M |
| Cash from Operations | -87.87M | -205.10M | -408.28M | -550.10M | -594.74M |
| Capital Expenditure | -403.00K | -478.00K | -525.00K | -807.00K | -773.00K |
| Sale of Property, Plant, and Equipment | -- | 99.00K | 99.00K | 99.00K | 99.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -403.00K | -379.00K | -426.00K | -708.00K | -674.00K |
| Total Debt Issued | 365.45M | 365.45M | 365.45M | -- | -- |
| Total Debt Repaid | 0.00 | 0.00 | -1.59M | -- | -- |
| Issuance of Common Stock | 18.83M | 44.28M | 47.48M | 68.41M | 461.04M |
| Repurchase of Common Stock | -57.00K | -44.00K | -41.00K | -69.00K | -11.04M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -234.98M | -260.36M | -258.77M | 43.26M | -55.50M |
| Cash from Financing | 149.24M | 149.33M | 152.53M | 111.61M | 394.50M |
| Foreign Exchange rate Adjustments | -659.00K | 890.00K | 259.00K | -130.00K | 135.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.31M | -55.26M | -255.92M | -439.33M | -200.78M |